Provided by Tiger Fintech (Singapore) Pte. Ltd.

Taysha Gene Therapies, Inc.

2.10
+0.200010.53%
Post-market: 2.140.0400+1.90%19:55 EDT
Volume:6.34M
Turnover:13.47M
Market Cap:430.61M
PE:-5.88
High:2.28
Open:1.86
Low:1.85
Close:1.90
Loading ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Mar

Buy Rating Reiterated for Taysha Gene Therapies Amid Positive Clinical Data and Strong Financial Position

TIPRANKS
·
02 Mar

Taysha Gene Therapies’ Positive Earnings Call Highlights

TIPRANKS
·
28 Feb

Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position

TIPRANKS
·
27 Feb

Taysha Gene Therapies Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
27 Feb

Q4 2024 Taysha Gene Therapies Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

Taysha Gene Therapies Reports 2024 Financial Results

TIPRANKS
·
27 Feb

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
27 Feb

Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability

TIPRANKS
·
27 Feb

Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

Taysha Gene Therapies Q4 EPS $(0.07) Beats $(0.08) Estimate, Sales $2.02M Miss $2.31M Estimate

Benzinga
·
26 Feb

Press Release: Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
26 Feb

Taysha Gene Therapies Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
24 Feb

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

GlobeNewswire
·
19 Feb

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Feb

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Feb

Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham

Dow Jones
·
06 Jan

Taysha Gene Therapies: Promising Developments and Strategic Investment Opportunity

TIPRANKS
·
06 Jan

Acelyrin Leads The Charge With 2 Other US Penny Stocks

Simply Wall St.
·
06 Jan